Transfer of Shares
May 06 2009 - 4:14AM
UK Regulatory
TIDMNWBS TIDMNWBT
RNS Number : 7501R
Northwest Biotherapeutics Inc
06 May 2009
Northwest Biotherapeutics, Inc.
(the "Company")
Transfer of Shares from Reg S Line (NWBS) to Unrestricted Line (NWBT)
Bethesda, MD Northwest Biotherapeutics, Inc. (AIM: NWBS and NWBT; OTC BB: NWBO)
announces today that 1,177,754 shares have been migrated to the unrestricted
line (ISIN: US66737P5017) from the Reg S restricted line (ISIN: USU666161000).
The shares were transferred in the following amounts and on the following dates:
+-----------------------------------------+-----------------------------------------+
| Date of transfer | Number of shares |
| | |
+-----------------------------------------+-----------------------------------------+
| 30 November 2007 | 799 |
| | |
+-----------------------------------------+-----------------------------------------+
| 20 December 2007 | 133 |
| | |
+-----------------------------------------+-----------------------------------------+
| 15 September 2008 | 1,052,632 |
| | |
+-----------------------------------------+-----------------------------------------+
| 19 March 2009 | 2,000 |
| | |
+-----------------------------------------+-----------------------------------------+
| 7 April 2009 | 122,190 |
+-----------------------------------------+-----------------------------------------+
No new shares have been issued and the transfers arose by virtue of the
expiration of the restrictions on the stock under U.S. securities law. Following
the transfer of these shares, the Company has a total of 45,069,972 issued and
outstanding common shares of 0.001 each in the Company. Following the transfers,
39,183,124 common shares of 0.001 each in the Company will be traded on AIM
under the ticker NWBT, the "Reg S line" and 5,886,848 common shares of 0.001
each in the Company will be traded on AIM under the ticker NWBT, the
"unrestricted line".
Dealings in the shares under the ticker NWBT are expected to commence trading on
AIM on 12 May 2009.
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on developing
immunotherapy products that treat cancers more effectively than current
treatments, without toxicity, on a cost-effective basis. The Company has two
broad platform technologies: dendritic cell-based vaccines, and therapeutic
antibodies. The Company is currently conducting a large clinical trial in
Glioblastoma multiforme, which is designed and powered to serve as a pivotal
trial. The Company has also received clearance from the FDA for a large Phase
III trial in prostate cancer, and clearance from the FDA for Phase I trials in
five other cancers. The Company also has a second technology platform, involving
monoclonal antibodies to CXCR4, which is at the late pre-clinical development
stage.
For further information, please visit the company web site at www.nwbio.com.
Disclaimer
Statements made in this news release that are not historical facts are
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. Words such as "expects," "believes," "intends,"
and similar expressions are intended to identify forward-looking statements.
Actual results may differ materially from those projected in any forward-looking
statement. Specifically, there are a number of important factors that could
cause actual results to differ materially from those anticipated. Additional
information on these and other factors, which could affect the company's
results, is included in its Securities and Exchange Commission ("SEC") filings.
Finally, there may be other factors not mentioned above or included in the
company's SEC filings that may cause actual results to differ materially those
projected in any forward-looking statement. You should not place undue reliance
on any forward-looking statements. The company assumes no obligation to update
any forward-looking statements as a result of new information, future events or
developments, except as required by securities laws.
For further information, please contact:
+----------------------------------------------------------------+----------------------+
| Northwest Biotherapeutics, Inc. | |
+----------------------------------------------------------------+----------------------+
| Alton L. Boynton, Chief Executive Officer | +1 240 497 9024 |
+----------------------------------------------------------------+----------------------+
| | |
+----------------------------------------------------------------+----------------------+
| Buchanan Communications | |
+----------------------------------------------------------------+----------------------+
| Lisa Baderoon (lisab@buchanan.uk.com) / Mary-Jane Johnson / | +44 (0)20 7466 5000 |
| Catherine Breen | |
+----------------------------------------------------------------+----------------------+
| | |
+----------------------------------------------------------------+----------------------+
| Collins Stewart Europe Limited | |
+----------------------------------------------------------------+----------------------+
| Adrian Hadden/ Adam Cowen | +44 (0)20 7523 8350 |
+----------------------------------------------------------------+----------------------+
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCCKAKDFBKKNPK
Northw.Bio Regs (LSE:NWBS)
Historical Stock Chart
From May 2024 to Jun 2024
Northw.Bio Regs (LSE:NWBS)
Historical Stock Chart
From Jun 2023 to Jun 2024
